USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Daicel-evonik Ltd.

USPTO PatentsView assignee record - 21 granted patents across 25 technology areas, recorded in grant years 2015–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C08L (Compositions OF Macromolecular Compounds).

RSS updates for this company

The verdict

According to USPTO PatentsView, Daicel-evonik ranks #13,939 of 49,997 tracked US assignees by granted-patent volume, with 21 patents across 25 technology areas.

#13,939
of 49,997 US assignees by volume
Top 27%
by Innovation Score (43.8/100)
11.4
avg claims per patent
+33%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R13939 · Foreign Corporation #13,939 · 21 grants

GRANTS-SMALL · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-PAR · TYPE-FRNCORP · VEL-UP · BOOK-FULL

  • GRANTS-SMALL 21 grants
  • MID-PACK #13,939/49,997
  • PHOTO-FINISH Curiteva
  • CPC-FOCUS C08L · 25 areas
  • INNOV-PAR 43.8/100
  • CLAIMS-PAR 11.4 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • VEL-UP +33% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Curiteva, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Daicel-evonik’s 43.8 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Daicel-evonik

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Daicel-evonik's Innovation Score is 43.8/100 (top 27% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Daicel-evonik?

Each dot is one of Daicel-evonik’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Daicel-evonik’s own 11.4 claims/patent is at or below the 13.4 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Daicel-evonik vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 20.920.92121.1 0510152025 Granted patents (volume) Avg claims / patent Curiteva, Inc. - 21, 8.86CuritevaCustom-Pak, Inc. - 21, 20.24Custom-pakCytek Biosciences, Inc. - 21, 14.33Cytek BiosciencesDA International, Inc. - 21, 1.67DA InternationalDaizo Corporation - 21, 13.43DaizoData Systems Co., Ltd. - 21, 14.14Data SystemsDatometry, Inc. - 21, 18.62DatometryDehn SE + Co KG - 21, 9.71Dehn SE + KGDaicel-evonik Ltd. - 21, 11.38Daicel-evonik
Daicel-evonik vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Daicel-evonik's grants concentrate

Daicel-evonik Ltd. is a focused PatentsView assignee: 25 CPC subclasses with 61.9% of grants classified under C08L (Compositions OF Macromolecular Compounds). Peak complete grant year is 2024 (6 grants) versus a trough of 1 in 2015. By volume, Daicel-evonik sits between Curiteva, Inc. and Dehn SE + Co KG.

Daicel-evonik's three-year grant acceleration

Daicel-evonik Ltd. shows 9 grants in 2022–2024 against only 7 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Daicel-evonik's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Daicel-evonik holds 21 patents at rank #13,939, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Daicel-evonik

By rank, the assignees closest to #13,939 in granted patent volume.

Leaders in C08L (Compositions OF Macromolecular Compounds)

Other assignees with the most granted patents in Daicel-evonik's primary technology class.

Daicel-evonik's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

44 Top 27% higher than 73% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

02468 2015201620172018201920202021202220232024 6
USPTO utility patent grants by year · 2015–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Daicel-evonik Ltd. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 1 4.8%
2016 2 9.5%
2017 1 4.8%
2018 1 4.8%
2019 4 19.0%
2020 1 4.8%
2021 2 9.5%
2022 1 4.8%
2023 2 9.5%
2024 6 28.6%

Which technologies does Daicel-evonik Ltd. patent most?

Top 15 of 25 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

What to do with this data

Daicel-evonik Ltd.'s patent record in context - here's where to go next.

  • Daicel-evonik Ltd.'s lead technology class is C08L (Compositions OF Macromolecular Compounds), 61.9% of its portfolio - see every assignee active in that class. Explore C08L
  • Ranked #13,939 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Daicel-evonik Ltd. against Curiteva, Inc., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 43.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.